This article reviews advancements in the genetics of malignant hyperthermia, new technologies and approaches for its diagnosis, and the existing limitations of genetic testing for malignant hyperthermia. It also reviews the various RYR1-related disorders and phenotypes, such as myopathies, exertional rhabdomyolysis, and bleeding disorders, and examines the connection between these disorders and malignant hyperthermia
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle metabolism characterize...
Thesis (Ph.D. (Biochemistry))--North-West University, Potchefstroom Campus, 2008.Malignant hyperther...
Background and purposeAlthough several recent studies have implicated RYR1 mutations as a common cau...
This article reviews advancements in the genetics of malignant hyperthermia, new technologies and ap...
SummaryContentMalignant hyperthermia (MH) is a potentially lethal pharmacogenetic disorder that affe...
Malignant hyperthermia (MH) is a condition that manifests in susceptible individuals only on exposur...
INTRODUCTION: Malignant hyperthermia (MH) and exertional rhabdomyolysis (ERM) have long been conside...
Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre ca...
Malignant hyperthermia (MH) is a rare and life-threatening pharmacogenetic disorder triggered by vol...
Item does not contain fulltextBACKGROUND AND PURPOSE: Although several recent studies have implicate...
OBJECTIVE: The histopathological features of malignant hyperthermia (MH) and non-anaesthetic (mostly...
Background and purpose: Although several recent studies have implicated RYR1 mutations as a common c...
Malignant hyperthermia (MH) is an uncommon, lifethreatening pharmacogenetic disorder of the skeletal...
Objective: The histopathological features of malignant hyperthermia (MH) and non-anaesthetic (mostly...
Study of the genetics of the malignant hyperthermia syndrome began in families in which both maligna...
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle metabolism characterize...
Thesis (Ph.D. (Biochemistry))--North-West University, Potchefstroom Campus, 2008.Malignant hyperther...
Background and purposeAlthough several recent studies have implicated RYR1 mutations as a common cau...
This article reviews advancements in the genetics of malignant hyperthermia, new technologies and ap...
SummaryContentMalignant hyperthermia (MH) is a potentially lethal pharmacogenetic disorder that affe...
Malignant hyperthermia (MH) is a condition that manifests in susceptible individuals only on exposur...
INTRODUCTION: Malignant hyperthermia (MH) and exertional rhabdomyolysis (ERM) have long been conside...
Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre ca...
Malignant hyperthermia (MH) is a rare and life-threatening pharmacogenetic disorder triggered by vol...
Item does not contain fulltextBACKGROUND AND PURPOSE: Although several recent studies have implicate...
OBJECTIVE: The histopathological features of malignant hyperthermia (MH) and non-anaesthetic (mostly...
Background and purpose: Although several recent studies have implicated RYR1 mutations as a common c...
Malignant hyperthermia (MH) is an uncommon, lifethreatening pharmacogenetic disorder of the skeletal...
Objective: The histopathological features of malignant hyperthermia (MH) and non-anaesthetic (mostly...
Study of the genetics of the malignant hyperthermia syndrome began in families in which both maligna...
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle metabolism characterize...
Thesis (Ph.D. (Biochemistry))--North-West University, Potchefstroom Campus, 2008.Malignant hyperther...
Background and purposeAlthough several recent studies have implicated RYR1 mutations as a common cau...